Return to Publications
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.

Return to Publications  |  Return to CINJ Home
The Cancer Institute of New Jersey's Cancer Connection, June 2012

Your link to the latest news on research, treatment, prevention and education from the state's only

National Cancer Institute-designated Comprehensive Cancer Center



CINJ's Celebration of National Cancer Survivors Day is Sunday, June 10


Survivors Day 2012

"iSurvive...iThrive!" will be a morning of informative educational sessions about healthy lifestyles and the importance of technology in cancer advances followed by an interactive lunch with a live cooking demonstration. The event will be held at The Cancer Institute of New Jersey (CINJ) in New Brunswick. There is no cost to attend, but registration is required. Registration closes Tuesday, June 5.Read more

Renewal of Prestigious National Designation Reaffirms CINJ as a Statewide Resource


CINJ Designation

The Cancer Institute of New Jersey was recently awarded renewal of its Comprehensive Cancer Center designation from the National Cancer Institute. This prestigious designation is granted competitively to institutions characterized by scientific excellence and the ability to bring research discoveries to patients. "The national designation of the renowned Cancer Institute of New Jersey continues a record of scientific excellence and will usher in a new era of advanced diagnostic and treatment technologies for Garden State residents," said Governor Chris Christie.Read more

Drug Compound Restores Tumor Suppressor Function of Mutated
p53 Protein


Darren Carpizo, MD, PhD

Investigators at The Cancer Institute of New Jersey and the Institute for Advanced Study in Princeton have identified a drug compound that reactivates a primary function in a mutated form of the p53 protein - the ability to suppress cancer tumors. While more research is needed, the authors, led by CINJ surgical oncologist Darren Carpizo, MD, PhD, say the new drug compound could have implications for some 32,000 cancer patients affected annually by this particular p53 mutation.Read more

Advancing Personalized Cancer Treatments through 'Precision Medicine'


Precision Medicine

With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over "one-size-fits-all" methods. The Cancer Institute of New Jersey has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer - an initiative known as "precision medicine" - also known to many as "personalized medicine."Read more

Low Skin Cancer Screening Rates for U.S. Hispanics Show Need for Interventions


Elliot J. Coups, PhD

When it comes to getting screened for skin cancer, only one in 14 U.S. Hispanic adults is shown to have ever gone through the process, compared to one in four non-Hispanic white adults. Research from The Cancer Institute of New Jersey shows socioeconomic factors such as lack of health insurance and poor access to healthcare serve as barriers for Hispanics who might otherwise receive this potentially lifesaving check-up.Read more

RWJMS logo    CINJ logo        NCI logo 

CINJ Office of Communications  ·  195 Little Albany Street  ·  New Brunswick, NJ  ·  732-235-9871

                        Like us on Facebook                     Join the CINJ Mailing List